Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Adenoid Cystic 1

Interventions

Docetaxel 4enzalutamide 3darolutamide 3cabazitaxel 3Pluvicto 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2Nivolumab 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1alovudine 1abiraterone 1Standard of Care 1Single Photon Emission Computed Tomography Computed Tomography 1Selegiline 1Radium-223 1Radiosurgery 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-resistant Prostate Cancer × 177Lu-EB-PSMA-617 × Clear all
NCT03403595 2018-01-18

177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer

Peking Union Medical College Hospital

Phase 1 Unknown
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡